These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8993356)

  • 21. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
    Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS
    J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice.
    Briles DE; King JD; Gray MA; McDaniel LS; Swiatlo E; Benton KA
    Vaccine; 1996 Jun; 14(9):858-67. PubMed ID: 8843627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.
    Roche AM; Weiser JN
    Infect Immun; 2010 May; 78(5):2231-9. PubMed ID: 20231407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence.
    Talkington DF; Crimmins DL; Voellinger DC; Yother J; Briles DE
    Infect Immun; 1991 Apr; 59(4):1285-9. PubMed ID: 2004810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.
    Roche H; Ren B; McDaniel LS; Håkansson A; Briles DE
    Infect Immun; 2003 Aug; 71(8):4498-505. PubMed ID: 12874329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.
    Wagner-Muñiz DA; Haughney SL; Kelly SM; Wannemuehler MJ; Narasimhan B
    Front Immunol; 2018; 9():325. PubMed ID: 29599766
    [No Abstract]   [Full Text] [Related]  

  • 30. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
    Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC
    Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
    Daniels CC; Coan P; King J; Hale J; Benton KA; Briles DE; Hollingshead SK
    Infect Immun; 2010 May; 78(5):2163-72. PubMed ID: 20194601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.
    Miyaji EN; Vadesilho CF; Oliveira ML; Zelanis A; Briles DE; Ho PL
    Clin Vaccine Immunol; 2015 Feb; 22(2):213-20. PubMed ID: 25520146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.
    Yu J; Li B; Chen X; Lu J; Wang D; Gu T; Kong W; Wu Y
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29610257
    [No Abstract]   [Full Text] [Related]  

  • 36. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
    J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.
    Crain MJ; Waltman WD; Turner JS; Yother J; Talkington DF; McDaniel LS; Gray BM; Briles DE
    Infect Immun; 1990 Oct; 58(10):3293-9. PubMed ID: 1698178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.
    Piao Z; Akeda Y; Takeuchi D; Ishii KJ; Ubukata K; Briles DE; Tomono K; Oishi K
    Vaccine; 2014 Sep; 32(43):5607-13. PubMed ID: 25132335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.
    Richards L; Ferreira DM; Miyaji EN; Andrew PW; Kadioglu A
    Immunobiology; 2010 Apr; 215(4):251-63. PubMed ID: 20071053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized and can protect splenectomized mice from infection with Streptococcus pneumoniae.
    Coats MT; Benjamin WH; Hollingshead SK; Briles DE
    Vaccine; 2005 Jul; 23(33):4257-62. PubMed ID: 16005736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.